UK Medicines Information
Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study
Information type:
Randomised controlled trials
Source:
Lancet Public Health
Specialities:
Infection and infectious diseases
Summary
This open-label study (n=484) found dolutegravir (50mg OD) to be non-inferior (1y analysis) and superior (2y analysis) to darunavir 800mg/ritonavir 100mg OD in treatment-naïve pts with HIV-1; HIV-1 RNA <50 copies/mL at wk 48 was achieved in 90% and 83%, respectively (p=0.025).
UKMi comment
A Commentary article discussing the results of this study is available at the link below.
Related links:
Comment